Entering text into the input field will update the search result below

BeyondSpring extends slump; analyst calls regulatory setback “somewhat surprising”

Dec. 03, 2021 9:29 AM ETBeyondSpring Inc. (BYSI)By: Dulan Lokuwithana, SA News Editor1 Comment

Wall street sign in New York with New York Stock Exchange background

naphtalina/iStock via Getty Images

  • After the FDA rejection of its combination therapy containing plinabulin for chemotherapy-induced neutropenia (CIN) led to a selloff on Wednesday, BeyondSpring (NASDAQ:BYSI) continues to trade lower with a ~5.0% decline in the pre-market.
  • However, one Wall Street

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.